SCHEMBL2637650

SCHEMBL2637650

CCOc1cc(CP(=O)(O)O)ccc1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.53
MAPT P10636 3/20 0.53
HSD17B10 Q99714 2/20 0.53
KDM4E B2RXH2 2/20 0.53
POLB P06746 2/20 0.53
MAPK1 P28482 2/20 0.53
MEN1 O00255 1/20 0.53
HPGD P15428 1/20 0.53
KMT2A Q03164 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
NPC1 O15118 1/20 0.43
USP2 O75604 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CREBBP Q92793 1/20 0.42
ENPP2 Q13822 1/20 0.41
S1PR2 O95136 1/20 0.40
S1PR1 P21453 1/20 0.40
S1PR3 Q99500 1/20 0.40
LPAR2 Q9HBW0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2636910 0.84 ALDH1A1 (0.61) ALDH1A1HSD17B10MAPK1PGK1PGK2
SCHEMBL2030320 0.83 ALDH1A1 (0.51) ALDH1A1MAPTHSD17B10KDM4EPOLB
SCHEMBL3277259 0.78 ALDH1A1 (0.66) ALDH1A1MAPTHSD17B10KDM4EPOLB
SCHEMBL11440361 0.76 ALDH1A1 (0.63) ALDH1A1MAPTHSD17B10KDM4EPOLB
SCHEMBL17058206 0.75 ALDH1A1 (0.61) ALDH1A1MAPTHSD17B10KDM4EPOLB
SCHEMBL9275830 0.75 PGK1 (0.50) ALDH1A1ENPP2PGK1PGK2TDP1
SCHEMBL3726422 0.74 ALDH1A1 (0.51) ALDH1A1MAPTHSD17B10KDM4EPOLB
SCHEMBL21605365 0.74 ALDH1A1 (0.59) ALDH1A1MAPTHSD17B10KDM4EPOLB
SCHEMBL2860898 0.74 TLR7 (0.40) MAPTKDM4EPOLBL3MBTL1SMN1; SMN2
SCHEMBL2637408 0.73 ALDH1A1 (0.59) ALDH1A1MAPTHSD17B10KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096624-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2015-08-04 US disclosed
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2013-09-05 US disclosed
EP-2438056-A2 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2012-04-11 EP disclosed
WO-2010141406-A2 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS ALDH1A1 1117/4885MAPT 2952/4885HSD17B10 4560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.